Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines

BACKGROUND: Targeting of class I histone deacetylases (HDACs) exerts antineoplastic actions in various cancer types by modulation of transcription, upregulation of tumor suppressors, induction of cell cycle arrest, replication stress and promotion of apoptosis. Class I HDACs are often deregulated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinkerneil, Maria, Hoffmann, Michèle J., Kohlhof, Hella, Schulz, Wolfgang A., Niegisch, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153417/
https://www.ncbi.nlm.nih.gov/pubmed/27250763
http://dx.doi.org/10.1007/s11523-016-0444-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153417/
https://www.ncbi.nlm.nih.gov/pubmed/27250763
http://dx.doi.org/10.1007/s11523-016-0444-7

Ejemplares similares